Medulloblastoma: Difference between revisions

Jump to navigation Jump to search
Jensflorian (talk | contribs)
+ infobox
Jensflorian (talk | contribs)
 
Line 150: Line 150:
**Infantile, p53 wildtype: Usu. desmoplastic/nodular, 10q loss.
**Infantile, p53 wildtype: Usu. desmoplastic/nodular, 10q loss.
**SHH-p53 mutant: Usu. large cell/anaplastic, 17q loss.
**SHH-p53 mutant: Usu. large cell/anaplastic, 17q loss.
*Group 3 (approx. 20%).
*Non WNT/Non SHH:
**Classic and large cell/anaplastic, MYC amplification, isochromosome 17q.
**Group 3 (approx. 20%).
*Group 4 (approx. 40%).
***Classic and large cell/anaplastic, MYC amplification, isochromosome 17q.
**Classic phenotype, MYCN amplification, isodicentric 17q.
**Group 4 (approx. 40%).
** Group 3+4 are often designated together as Non-Wnt/Non-SHH tumours.
***Classic phenotype, MYCN amplification, isodicentric 17q.
Note: Within Group 3+4 two  or  more  of  chromosome  7  gain,  chromo­some 8 loss, and chromosome 11 loss separates standard risk medulloblastoma samples into favorable and classifies the remaining i17q diploid cases as high-risk.


==Prognosis==
==Prognosis==